

Magnus Gisslen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3524040/publications.pdf>

Version: 2024-02-01

95
papers

5,380
citations

94381

37
h-index

88593

70
g-index

103
all docs

103
docs citations

103
times ranked

6050
citing authors

#	ARTICLE	IF	CITATIONS
1	Cerebrospinal Fluid Viral Load Across the Spectrum of Untreated Human Immunodeficiency Virus Type 1 (HIV-1) Infection: A Cross-Sectional Multicenter Study. <i>Clinical Infectious Diseases</i> , 2022, 75, 493-502.	2.9	15
2	Longevity of anti-spike and anti-nucleocapsid antibodies after COVID-19 in solid organ transplant recipients compared to immunocompetent controls. <i>American Journal of Transplantation</i> , 2022, 22, 1245-1252.	2.6	13
3	The ratio of cardiac troponin T to troponin I may indicate non-necrotic troponin release among COVID-19 patients. <i>Clinica Chimica Acta</i> , 2022, 527, 33-37.	0.5	7
4	Severe multisystem inflammatory syndrome (MIS-C/A) after confirmed SARS-CoV-2 infection: a report of four adult cases. <i>Infectious Diseases</i> , 2022, 54, 378-383.	1.4	4
5	A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data. <i>European Urology</i> , 2022, 81, 285-293.	0.9	40
6	Confirmed reinfection with SARS-CoV-2 during a pregnancy: A case report. <i>Clinical Case Reports (discontinued)</i> , 2022, 10, e05400.	0.2	1
7	The social patterning of Covid-19 vaccine uptake in older adults: A register-based cross-sectional study in Sweden. <i>Lancet Regional Health - Europe, The</i> , 2022, 15, 100331.	3.0	22
8	Stratification of COVID-19 patients based on quantitative immune-related gene expression in whole blood. <i>Molecular Immunology</i> , 2022, 145, 17-26.	1.0	4
9	Correlation between cerebrospinal fluid and plasma neurofilament light protein in treated HIV infection: results from the COBRA study. <i>Journal of NeuroVirology</i> , 2022, 28, 54-63.	1.0	9
10	Blood biomarkers for HIV infection with focus on neurologic complications – A review. <i>Acta Neurologica Scandinavica</i> , 2022, 146, 56-60.	1.0	2
11	Viral Antigen and Inflammatory Biomarkers in Cerebrospinal Fluid in Patients With COVID-19 Infection and Neurologic Symptoms Compared With Control Participants Without Infection or Neurologic Symptoms. <i>JAMA Network Open</i> , 2022, 5, e2213253.	2.8	35
12	Severe COVID-19 in people 55 and older during the first year of the pandemic in Sweden. <i>Journal of Internal Medicine</i> , 2022, 292, 641-653.	2.7	7
13	No effect of remdesivir or betamethasone on upper respiratory tract SARS-CoV-2 RNA kinetics in hospitalised COVID-19 patients: a retrospective observational study. <i>Infectious Diseases</i> , 2022, 54, 703-712.	1.4	3
14	Contagiousness in treated HIV-1 infection. <i>Infectious Diseases</i> , 2021, 53, 1-8.	1.4	8
15	Cerebrospinal fluid CXCL10 is associated with the presence of low level CSF HIV during suppressive antiretroviral therapy. <i>Journal of Neuroimmunology</i> , 2021, 353, 577493.	1.1	4
16	Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: A nationwide retrospective cohort study. <i>Lancet Regional Health - Europe, The</i> , 2021, 4, 100105.	3.0	77
17	Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. <i>PLoS ONE</i> , 2021, 16, e0250987.	1.1	30
18	Increased immune activation and signs of neuronal injury in HIV-negative people on preexposure prophylaxis. <i>Aids</i> , 2021, 35, 2129-2136.	1.0	6

#	ARTICLE	IF	CITATIONS
19	Swedish Covid-19 Investigation for Future Insights – A Population Epidemiology Approach Using Register Linkage (SCIFI-PEARL). <i>Clinical Epidemiology</i> , 2021, Volume 13, 649-659.	1.5	26
20	Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. <i>EBioMedicine</i> , 2021, 70, 103512.	2.7	106
21	Low admission protein C levels are a risk factor for disease worsening and mortality in hospitalized patients with COVID-19. <i>Thrombosis Research</i> , 2021, 204, 13-15.	0.8	14
22	Neurochemical biomarkers to study CNS effects of COVID-19: A narrative review and synthesis. <i>Journal of Neurochemistry</i> , 2021, 159, 61-77.	2.1	21
23	No difference in biomarkers of ischemic heart injury and heart failure in patients with COVID-19 who received treatment with chloroquine phosphate and those who did not. <i>PLoS ONE</i> , 2021, 16, e0256035.	1.1	1
24	CSF Biomarkers in Patients With COVID-19 and Neurologic Symptoms. <i>Neurology</i> , 2021, 96, e294-e300.	1.5	118
25	Neurochemical signs of astrocytic and neuronal injury in acute COVID-19 normalizes during long-term follow-up. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
26	Serum-IgG responses to SARS-CoV-2 after mild and severe COVID-19 infection and analysis of IgG non-responders. <i>PLoS ONE</i> , 2020, 15, e0241104.	1.1	158
27	Serum neopterin levels in relation to mild and severe COVID-19. <i>BMC Infectious Diseases</i> , 2020, 20, 942.	1.3	42
28	Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. <i>Neurology</i> , 2020, 95, e1754-e1759.	1.5	304
29	Antiretroviral treatment for HIV infection: Swedish recommendations 2019. <i>Infectious Diseases</i> , 2020, 52, 295-329.	1.4	13
30	Cognitive and Neuronal Link With Inflammation: A Longitudinal Study in People With and Without HIV Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 617-625.	0.9	19
31	Title is missing!. , 2020, 15, e0241104.		0
32	Title is missing!. , 2020, 15, e0241104.		0
33	Title is missing!. , 2020, 15, e0241104.		0
34	Title is missing!. , 2020, 15, e0241104.		0
35	Title is missing!. , 2020, 15, e0241104.		0
36	Title is missing!. , 2020, 15, e0241104.		0

#	ARTICLE	IF	CITATIONS
37	Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection. <i>Infectious Diseases</i> , 2019, 51, 838-846.	1.4	7
38	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	4.5	455
39	Defining cerebrospinal fluid HIV RNA escape. <i>Aids</i> , 2019, 33, S107-S111.	1.0	40
40	Plasma concentration of neurofilament light chain protein decreases after switching from tenofovir disoproxil fumarate to tenofovir alafenamide fumarate. <i>PLoS ONE</i> , 2019, 14, e0226276.	1.1	14
41	Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells. <i>Clinical Infectious Diseases</i> , 2019, 69, 1345-1352.	2.9	58
42	Elevated cerebrospinal fluid Galectin-9 is associated with central nervous system immune activation and poor cognitive performance in older HIV-infected individuals. <i>Journal of NeuroVirology</i> , 2019, 25, 150-161.	1.0	26
43	Cerebrospinal Fluid Concentrations of the Synaptic Marker Neurogranin in Neuro-HIV and Other Neurological Disorders. <i>Current HIV/AIDS Reports</i> , 2019, 16, 76-81.	1.1	9
44	CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, e512.	3.1	50
45	Title is missing!. , 2019, 14, e0226276.		0
46	Title is missing!. , 2019, 14, e0226276.		0
47	Title is missing!. , 2019, 14, e0226276.		0
48	Title is missing!. , 2019, 14, e0226276.		0
49	Structural Brain Abnormalities in Successfully Treated HIV Infection: Associations With Disease and Cerebrospinal Fluid Biomarkers. <i>Journal of Infectious Diseases</i> , 2018, 217, 69-81.	1.9	40
50	Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment. <i>Aids</i> , 2018, 32, 2171-2178.	1.0	37
51	Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. <i>Journal of NeuroVirology</i> , 2018, 24, 695-701.	1.0	35
52	Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 761-770.	1.5	114
53	Antiretroviral treatment for HIV infection: Swedish recommendations 2016. <i>Infectious Diseases</i> , 2017, 49, 1-34.	1.4	24
54	Sweden, the first country to achieve the Joint United Nations Programme on HIV/AIDS (UNAIDS)/World Health Organization (WHO) 90-90-90 continuum of HIV care targets. <i>HIV Medicine</i> , 2017, 18, 305-307.	1.0	108

#	ARTICLE	IF	CITATIONS
55	Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 1822-1825.	1.9	53
56	Blood-brain barrier integrity, intrathecal immunoactivation, and neuronal injury in HIV. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e300.	3.1	36
57	Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. <i>EBioMedicine</i> , 2016, 3, 135-140.	2.7	360
58	Highlights of the Global HIV-1 CSF Escape Consortium Meeting, 9 June 2016, Bethesda, MD, USA. <i>Journal of Virus Eradication</i> , 2016, 2, 243-250.	0.3	22
59	The cerebrospinal fluid biomarker profile in an HIV-infected subject with Alzheimer's disease. <i>AIDS Research and Therapy</i> , 2015, 12, 23.	0.7	17
60	Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy. <i>Current HIV/AIDS Reports</i> , 2015, 12, 280-288.	1.1	93
61	Biomarker Evidence of Axonal Injury in Neuroasymptomatic HIV-1 Patients. <i>PLoS ONE</i> , 2014, 9, e88591.	1.1	128
62	Cerebrospinal Fluid (CSF) Neuronal Biomarkers across the Spectrum of HIV Infection: Hierarchy of Injury and Detection. <i>PLoS ONE</i> , 2014, 9, e116081.	1.1	95
63	Risk of HIV transmission from patients on antiretroviral therapy: A position statement from the Public Health Agency of Sweden and the Swedish Reference Group for Antiviral Therapy. <i>Scandinavian Journal of Infectious Diseases</i> , 2014, 46, 673-677.	1.5	24
64	Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. <i>Aids</i> , 2014, 28, 2251-2258.	1.0	125
65	Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. <i>Journal of Neuroinflammation</i> , 2013, 10, 62.	3.1	55
66	Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection. <i>Journal of NeuroImmune Pharmacology</i> , 2013, 8, 1147-1158.	2.1	37
67	Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. <i>Aids</i> , 2012, 26, 1765-1774.	1.0	212
68	Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 997-1000.	1.5	14
69	The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?. <i>BMC Infectious Diseases</i> , 2011, 11, 356.	1.3	195
70	Treatment Intensification Has no Effect on the HIV-1 Central Nervous System Infection in Patients on Suppressive Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 55, 590-596.	0.9	62
71	Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. <i>AIDS Research and Therapy</i> , 2010, 7, 15.	0.7	186
72	HIV-1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment. <i>Journal of Infectious Diseases</i> , 2010, 202, 1819-1825.	1.9	255

#	ARTICLE	IF	CITATIONS
73	Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. <i>BMC Neurology</i> , 2009, 9, 63.	0.8	126
74	Reduction of the HIV-1 reservoir in resting CD4+ T-lymphocytes by high dosage intravenous immunoglobulin treatment: a proof-of-concept study. <i>AIDS Research and Therapy</i> , 2009, 6, 15.	0.7	29
75	Persistent Intrathecal Immune Activation in HIV-1-Infected Individuals on Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 47, 168-173.	0.9	96
76	Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. <i>Neurology</i> , 2007, 69, 1536-1541.	1.5	77
77	Immune Activation of the Central Nervous System Is Still Present after >4 Years of Effective Highly Active Antiretroviral Therapy. <i>Journal of Infectious Diseases</i> , 2007, 196, 1779-1783.	1.9	164
78	Elevated Cerebrospinal Fluid Neurofilament Light Protein Concentrations Predict the Development of AIDS Dementia Complex. <i>Journal of Infectious Diseases</i> , 2007, 195, 1774-1778.	1.9	103
79	CSF neurofilament protein (NFL) is a marker of active HIV-related neurodegeneration. <i>Journal of Neurology</i> , 2007, 254, 1026-1032.	1.8	110
80	Defining and Evaluating HIV-Related Neurodegenerative Disease and Its Treatment Targets: A Combinatorial Approach to Use of Cerebrospinal Fluid Molecular Biomarkers. <i>Journal of NeuroImmune Pharmacology</i> , 2007, 2, 112-119.	2.1	45
81	Antiretroviral treatment of HIV infection: Swedish recommendations 2005. <i>Scandinavian Journal of Infectious Diseases</i> , 2006, 38, 86-103.	1.5	7
82	Cerebrospinal Fluid Viral Loads Reach Less than 2 Copies/ML in HIV-1-Infected Patients with Effective Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2006, 11, 833-838.	0.6	27
83	Cerebrospinal fluid signs of neuronal damage after antiretroviral treatment interruption in HIV-1 infection. <i>AIDS Research and Therapy</i> , 2005, 2, 6.	0.7	47
84	Cerebrospinal Fluid HIV-1 Infection Usually Responds Well to Antiretroviral Treatment. <i>Antiviral Therapy</i> , 2005, 10, 701-707.	0.6	44
85	A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial. <i>Antiviral Therapy</i> , 2005, 10, 735-743.	0.6	51
86	Clinical Application of Cerebrospinal Fluid Neopterin Concentrations in HIV Infection. <i>Pteridines</i> , 2004, 15, 102-106.	0.5	16
87	Antiretroviral treatment of central nervous system HIV-1 infection: a review. <i>HIV Medicine</i> , 2001, 2, 97-104.	1.0	39
88	Higher HIV-1 RNA cutoff level required in cerebrospinal fluid than in blood to predict positive HIV-1 isolation. <i>Journal of Medical Virology</i> , 2000, 62, 9-13.	2.5	11
89	Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients. <i>Journal of Neuroimmunology</i> , 2000, 102, 51-55.	1.1	41
90	Cerebrospinal Fluid Antibodies Directed against Neuron-Associated Gangliosides in HIV-1 Infection. <i>Infection</i> , 2000, 28, 143-148.	2.3	7

#	ARTICLE	IF	CITATIONS
91	Cerebrospinal Fluid and Plasma Viral Load in HIV-1-infected Patients with Various Anti-retroviral Treatment Regimens. <i>Scandinavian Journal of Infectious Diseases</i> , 2000, 32, 365-369.	1.5	27
92	Cerebrospinal Fluid Viral Load, Intrathecal Immunoactivation, and Cerebrospinal Fluid Monocytic Cell Count in HIV-1 Infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 1999, 21, 271.	0.9	100
93	Markers of Immune Stimulation in the Cerebrospinal Fluid During HIV Infection: A longitudinal study. <i>Scandinavian Journal of Infectious Diseases</i> , 1994, 26, 523-533.	1.5	55
94	GM- β CSF expands the eosinophilic compartment in chronic idiopathic neutropenia. <i>European Journal of Haematology</i> , 1990, 44, 315-316.	1.1	2
95	Cerebrospinal Fluid Markers in the Management of Central Nervous System HIV Infection and the AIDS Dementia Complex. , 0 , 173-179.		0